Beruflich Dokumente
Kultur Dokumente
CLINICAL STUDY
TOPIC
Liu Defang, Guo Mingyang, Hu Yonghe, Liu Taihua, Yan Jiao, Luo Yong, Yun Mingdong, Yang Min, Zhang Jun,
Guo Linglin
aa
Liu Defang, Guo Mingyang, Hu Yonghe, Yan Jiao, Luo were given ginger-partitioned acupoint stimula-
Yong, Yun Mingdong, Yang Min, Zhang Jun, Guo Linglin, tion at Zusanli (ST 36) in addition to the ARDs. Pa-
Department of Integrated Traditional and Western Medicine tients in the combination treatment group were
on Rheumatism, General Hospital of Chengdu Military Area
given oral Sanhuangwuji powder,ginger-parti-
Command PLA, Chengdu 610083, China
Liu Taihua, Department of Dermatology, General Hospital
tioned acupoint stimulation at Zusanli (ST 36), and
of Chengdu Military Area Command Chinese People's Liber- ARDs. All patients were followed up for 2 months to
ation Army, Chengdu 610083, China evaluate clinical effects and safety. The study was
Supported by the Scientific Research Foundation of Sich- registered in the World Health Organization data-
uan Health Department (Study of the Regulatory Mecha- base at the General Hospital of Chengdu Military
nism of Th Cells in Rheumatoid Arthritis Treated with San- Area Command Chinese People's Liberation Army
huangylong Decoction and Its Component United With (ChiCTR- TCC12002824).
Methotrexate, No. 120573)
Correspondence to: Prof. Liu Defang, Department of Inte- RESULTS: The combination treatment group had
grated Traditional and Western Medicine on Rheumatism, significantly greater improvements in RA symp-
General Hospital of Chengdu Military Area Command PLA, toms, laboratory outcomes, and gastrointestinal
Chengdu 610083, China. liudefang199@163.com
symptom scores, compared with the other groups
Telephone: +86-28-86571107; +86-18683958336
Accepted: March 19, 2014
(P < 0.05). The peptic ulcer healing rate in the com-
bination treatment group was significantly greater
than that in the ARD treatment group (χ2 = 16.875,
P < 0.05) and the ginger-partitioned stimulation
Abstract group (χ2 = 6.171, P < 0.05).
OBjECTIVE: To observe the efficacy and safety of CONCLUSION: Combination treatment with gin-
oral Sanhuangwuji powder, anti-rheumatic drugs ger-partitioned acupoint stimulation at Zusanli (ST
(ARDs), and ginger-partitioned acupoint stimula- 36), oral Sanhuangwuji powder, and ARDs had a
tion at Zusanli (ST 36) on the treatment of rheuma- better clinical effect for RA with complicated peptic
toid arthritis (RA) complicated by peptic ulcer. ulcer, compared with ARD treatmentalone or in
combination with ginger-partitioned acupoint
METHODS: This prospective randomized con-
stimulation.
trolled study included 180 eligible inpatients and
outpatients randomly assigned to an ARD treat-
ment (n = 60), ginger-partitioned stimulation (n = © 2015 JTCM. All rights reserved.
60), or combination treatment (n = 60). Patients as-
signed to the ARD group were given oral celecoxib, Key words: Arthritis, rheumatoid; Peptic ulcer;
methotrexate, and esomeprazole. Patients as- Point ST 36 (Zusanli); Sanhuangwuji powder; Ran-
signed to theginger-partitioned stimulation group domized controlled trial
JTCM | www. journaltcm. com 273 June 15, 2015 | Volume 35 | Issue 3 |
Liu DF et al. / Clinical Study
JTCM | www. journaltcm. com 274 June 15, 2015 | Volume 35 | Issue 3 |
Liu DF et al. / Clinical Study
Excluded (n=20)
Not meeting inclusion criteria (n = 10)
Declined to participate (n = 6)
Other reasons (n = 4)
Randomized groups
(n = 3)
crine disorders; or impaired consciousness or psychiat- cold, spicy, or tough foods, and alcohol during the
ric disorders. Patients were also excluded if they partici- treatment. One treatment cycle lasted 4 weeks, and a
pated in any other clinical studies within the previous follow-up fiber-optic endoscopy was repeated after two
3 months, or for any other reasons at the discretion of cycles of treatment.
the investigators. Pregnant or lactating women were al-
so excluded. Outcome measures
Outcome measures included the number of swollen
Treatments joints, the number of tender joints, the duration of
ARD treatment. Patients were given 20-mg oral esome- morning stiffness, gripping strength, self-reported pain
prazole magnesium enteric-coated tablets (Astra Zene- score, DAS-28 RA disease activity score, a health assess-
ca, London, UK) once daily, 5 min before breakfast; ment questionnaire (HAQ) for quality of life, levels of
100-mg oral celecoxib capsules (Pfizer, New York, NY, serum rheumatoid factor (RF), anti-cyclic citrullinated
USA) twice daily; and 15-mg oral methotrexate tablets peptide (anti-CCP), ESR, and CRP. These were assessed
(Sine Pharmaceutical Co., Ltd., Shanghai, China) once at the baseline, and 4 and 8 weeks after treatment. Any
weekly. GI symptoms, such as abdominal pain, reflux, belch-
Ginger-partitioned stimulationof the Zusanli (ST 36) ing, and abdominal distension, were documented and
acupoint. Patients were administered ARD treatment semi-quantitatively scored. A GI endoscopy was per-
and ginger-partitioned stimulation at Zusanli (ST 36). formed at baseline and 8 weeks after treatment.
A 5-mm-thick fresh ginger slice was placed over Zusan-
li (ST 36) and the point was stimulated with the endur- Evaluation of RA treatment efficacy
able heat from a burning moxa-stick for 10-15 min. RA treatment efficacy outcomes were classified based
Moxibustion was performed twice daily. on ACR20, ACR50, and ACR70 improvement crite-
Combination treatment. Patients were administered ria, as established by the American College of Rheuma-
ARD treatment, moxibustion, and oral Sanhuangwuji tology.13 Briefly, ACR20 refers to a 20% improvement
powder (10 g per dose, three times a day). Sanhuang- in the number of tender and swollen joints and more
wuji powder was prepared by PLA Chengdu General than a 50% reduction in scores for at least three items
Hospital Pharmacy, and contained Huangqin (Radix out of: the pain visual analog scale (VAS), the pa-
Scutellariae Baicalensis) 15 g, Huanglian (Rhizoma Cop- tient-reported symptom score, the physician-reported
tidis) 10 g, Huangbai (Cortex Phellodendri Amurensis) symptom score, the HAQ, and RF, ESR, or CRP lev-
15 g, Dilong (Pheretima Aspergillum) 10 g, Haipiaoxi- els. ACR50 and ACR70 respectively refer to 50% and
ao (Endoconcha Sepiellae) 30 g, and Baiji (Rhizoma 70% improvements in the same metrics as ACR20. RA
Bletillae Striatae) 15 g. This powder was taken alone, treatment outcome was determined to be significantly
and the patients were instructed to avoid any raw, effective if ACR70 was achieved (primary symptoms,
JTCM | www. journaltcm. com 275 June 15, 2015 | Volume 35 | Issue 3 |
Liu DF et al. / Clinical Study
signs, RF, ESR, and CRP improved, with an overall im- RESULTS
provement in the score of > 70%); moderately effective
if ACR50 was achieved (primary symptoms, signs, RF,
Patient characteristics
ESR and CRP improved, with an overall improvement
The combination treatment group (n = 60) included
in the score of 20%-70%); or ineffective if ACR20 was
14 men and 46 women with a mean age of (56 ± 6)
not achieved (primary symptoms, signs, RF, ESR and
years (range 45-65 years), and a mean RA history of
CRP improved, with an overall improvement in the
(9 ± 5) years (range 2-20 years). The ARD treatment
score of < 20%). The primary symptoms and signs in-
group (n = 60) included 12 men and 48 women
cluded the number of swollen joints, the number of
aged (56 ±6) years (range 45-65 years), and a mean
tender joints, the duration of morning stiffness, the av-
RA history of (9 ± 6) years (range 1.5-21 years). The
erage gripping strength, and the pain VAS. The im-
provement rate was defined as the mean of the im- ginger-partitioned stimulation group (n = 60) includ-
provement percentages [(pre-treatment score − ed 13 men and 47 women aged (56 ± 6) years
post-treatment score)/pre-treatment score × 100%] for (range 45-65 years), with a mean RA history of (9 ±
the five outcome measures. 6) years (range 2.5-22 years). The three groups were
comparable in terms of sex, age, and history of RA
Evaluation of peptic ulcer treatment effect (P > 0.05).
All patients were followed up at 4 weeks and 8 weeks
to assess the GI symptom score and the clinical efficacy Clinical efficacy of RA treatment
of peptic ulcer treatment.14 Peptic ulcer treatment out- The clinical efficacy outcomes for the treatment of RA
come was determined to be ineffective if the reduction are shown in Table 1. At baseline, all groups were com-
in ulcer area was < 50%, with aggravation of abdomi- parable in terms of the number of swollen joints, num-
nal pain and symptoms of abdominal irritability; mod- ber of tender joints, duration of morning stiffness, pain
erately effective if the reduction in ulcer area was > VAS, HAQ score, and DAS-28 score (P > 0.05). Com-
50% , with the disappearance of abdominal pain and pared with the baseline measurements, significant im-
symptoms of abdominal irritability; or significantly ef- provements in the primary symptoms and signs were
fective if the ulcer, abdominal pain, and symptoms of observed in all groups 4 and 8 weeks after treatment
abdominal irritability disappeared, with all laboratory (P < 0.05). The combination treatment group had a
parameters returning to normal. The overall rate of treat- significantly greater improvement, compared with the
ment success was defined as the percentage of patients
ARD group (P < 0.05) and the ginger-partitioned stim-
exhibiting moderately or significantly effective treat-
ulation group (P < 0.05).
ment outcomes. The GI symptom score was semi-
quantitatively graded as follows: 0 points, no GI symp-
Laboratory efficacy of RA treatment
toms; 1 point, mild symptoms requiring no medication;
The laboratory efficacy outcomes for RA treatment
2 points, moderate symptoms with slight impairment
are shown in Table 2. At baseline, all groups were
in daily life; and 3 points, severe symptoms requiring
comparable with regard to platelet count, ESR, se-
medication, with serious impairment in daily life.
rum CRP level, serum RF level, and anti-CCP titer
Evaluation of endoscopic peptic ulcer treatment effi- (P > 0.05). Compared with baseline values, laborato-
cacy ry parameters improved significantly in the combina-
The efficacy of peptic ulcer treatmentby endoscopy tion treatment group 4 and 8 weeks after treatment
was assessed as previously described.15 Peptic ulcer treat- (P < 0.05). Fourweeks after treatment, the ARD
ment outcome was determined to be: clinically cured if treatment group exhibited significant improvements
the ulcer completely disappeared, and there was no ob- in platelet count, ESR, and serum CRP level (P <
vious edema; significantly effective if the ulcer disap- 0.05), but no significant changes in serum RF level
peared, but there was still obvious inflammation; mod- or anti-CCP titer (P > 0.05). Four weeks after treat-
erately effective if the reduction in ulcer area was > ment, there was a significant improvement in platelet
50%; or ineffective if the reduction in ulcer area was < count, ESR, serum CRP level, and serum RF level in
50%. the ginger-partitioned stimulation group (P < 0.05),
Statistical analysis but no significant alteration in the anti-CCP titer (P >
SPSS 12.0 (SPSS Inc., Chicago, IL, USA) was used for 0.05) compared with the baseline. These three treat-
statistical analysis. All continuous data are expressed as ment groups showed significant improvements in plate-
the mean ± standard deviation ( xˉ ± s), and were com- let count, ESR, serum CRP level, serum RF level, and
pared using analysis of variance followed by the least anti-CCP titer 8 weeks after treatment (P < 0.05), rela-
significant difference test. All categorical data were tive to the baseline. Eight weeks after treatment, the
compared using a multiple, independent samples combination treatment group had a significantly great-
non-parametric test. A P-value < 0.05 was considered er improvement in all parameters compared with the
statistically significant. ARD treatment group (P < 0.05).
JTCM | www. journaltcm. com 276 June 15, 2015 | Volume 35 | Issue 3 |
Liu DF et al. / Clinical Study
JTCM | www. journaltcm. com 277 June 15, 2015 | Volume 35 | Issue 3 |
Liu DF et al. / Clinical Study
Group n Time point (week) Abdominal pain Reflux Belching Abdominal distension
JTCM | www. journaltcm. com 278 June 15, 2015 | Volume 35 | Issue 3 |
Liu DF et al. / Clinical Study
JTCM | www. journaltcm. com 279 June 15, 2015 | Volume 35 | Issue 3 |
Liu DF et al. / Clinical Study
JTCM | www. journaltcm. com 280 June 15, 2015 | Volume 35 | Issue 3 |